增强基于毒素的肉毒中毒疫苗
本研究以重组全长肉毒神经毒素A1型(BoNT/A1)为候选疫苗,通过引入3个氨基酸突变(E224A/R363A/Y366F)消除催化活性获得M-BoNT/A1,小鼠模型中毒性较天然BoNT/A1降低超过10^6倍;再引入W1266A突变降低受体结合获得M-BoNT/A1W。M-BoNT/A1W接种可抵御10^6 LD50单位天然BoNT/A1攻击,M-BoNT/A1或M-BoNT/A1W接种对BoNT/A2亚型攻击提供同等保护。
要点
- M-BoNT/A1W在 ganglioside 结合口袋引入W1266A突变,降低受体结合以提升疫苗安全性。
- M-BoNT/A1W接种可抵御10^6 LD50单位天然BoNT/A1攻击。
- M-BoNT/A1或M-BoNT/A1W接种对天然BoNT/A2攻击提供同等保护。
核心结论
- M-BoNT/A1W具有多重毒素功能缺陷,可对BoNT/A攻击引发强效免疫应答,作为针对肉毒中毒和其他毒素介导疾病的疫苗策略。
研究设计与样本
- 本研究为实验性疫苗研究,比较重组全长BoNT/A1、LCHCN/A1和HCC/A1作为肉毒中毒候选疫苗。
- 通过工程化3个氨基酸突变(E224A/R363A/Y366F)至LC获得解毒的M-BoNT/A1,并进一步引入W1266A突变获得M-BoNT/A1W。
主要发现
- M-BoNT/A1在小鼠肉毒中毒模型中的毒性较天然BoNT/A1降低超过10^6倍。
- M-BoNT/A1W接种可抵御10^6 LD50单位天然BoNT/A1攻击。
- M-BoNT/A1或M-BoNT/A1W接种对天然BoNT/A2攻击提供同等保护。
- 接种M-BoNT/A1W后存活BoNT攻击的小鼠对LCHCN结构域产生优势抗体应答,对HCC的抗体应答则存在差异。
- M-BoNT/A1W接种小鼠的血清可中和BoNT/A1对培养神经元细胞的作用,且M-BoNT/A1W在细胞和小鼠两种检测中均引发强中和应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Botulinum neurotoxins (BoNT) are the most toxic proteins for humans. BoNTs are single chain proteins with an N-terminal light chain (LC) and a C-terminal heavy chain (HC). HC comprises a translocation domain (HCN) and a receptor binding domain (HCC). Currently, there are no approved vaccines against botulism. This study tests a recombinant, full-length BoNT/A1 versus LCHCN/A1 and HCC/A1 as vaccine candidates against botulism. Recombinant, full-length BoNT/A1 was detoxified by engineering 3-amino acid mutations (E224A/R363A/Y366F) (M-BoNT/A1) into the LC to eliminate catalytic activity, which reduced toxicity in a mouse model of botulism by >106-fold relative to native BoNT/A1. As a second step to improve vaccine safety, an additional mutation (W1266A) was engineered in the ganglioside binding pocket, resulting in reduced receptor binding, to produce M-BoNT/A1W. M-BoNT/A1W vaccination protected against challenge by 106 LD50 Units of native BoNT/A1, while M-BoNT/A1 or M-BoNT/A1W vaccination equally protected against challenge by native BoNT/A2, a BoNT subtype. Mice vaccinated with M-BoNT/A1W surviving BoNT challenge had dominant antibody responses to the LCHCN domain, but varied antibody responses to HCC. Sera from mice vaccinated with M-BoNT/A1W also neutralized BoNT/A1 action on cultured neuronal cells. The cell- and mouse-based assays measured different BoNT-neutralizing antibodies, where M-BoNT/A1W elicited a strong neutralizing response in both assays. Overall, M-BoNT/A1W, with defects in multiple toxin functions, elicits a potent immune response to BoNT/A challenge as a vaccine strategy against botulism and other toxin-mediated diseases.
引用
- Przedpelski A, Tepp WH, Zuverink M, et al. Enhancing toxin-based vaccines against botulism. Vaccine. 2018. PMID: 29307477. doi:10.1016/j.vaccine.2017.12.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。